Key statistics
As of last trade Nuvation Bio Inc (NUVB:NYQ) traded at 5.80, -40.56% below its 52-week high of 9.75, set on Dec 22, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.69 |
|---|---|
| High | 5.89 |
| Low | 5.64 |
| Bid | 5.79 |
| Offer | 5.80 |
| Previous close | 5.77 |
| Average volume | 4.45m |
|---|---|
| Shares outstanding | 342.83m |
| Free float | 276.72m |
| P/E (TTM) | -- |
| Market cap | 1.98bn USD |
| EPS (TTM) | -0.6399 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 16:53 GMT.
More ▼
- Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma
- Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
- Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
- Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
- Nuvation Bio to Participate in Upcoming Investor Conferences
More ▼
